Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs).
THE INDUSTRY LEADER IN MEMBRANE PROTEIN SOLUTIONS
Integral Molecular Breaks Ground on New Headquarters, Doubling in Size
5/24/2022
Lonza Early Development Services and Integral Molecular to Offer Complementary Expertise to Enhance Early De-risking of Biotherapeutics
4/25/2022
Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening
Cell Reports, 2022
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Journal of Clinical Investigation, 2022
THE INDUSTRY LEADER IN MEMBRANE PROTEIN SOLUTIONS
Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.
INDUSTRY EXPERIENCE
With 20+ years experience, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.
PROVEN QUALITY
Integral Molecular’s technologies have contributed to scientific discoveries featured in 350+ peer-reviewed publications.
OPEN COMMUNICATION
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.
Membrane Protein Solutions
Our full suite of Membrane Protein Solutions delivers diverse panels of functional MAbs
Our virus-like particles contain high levels of native membrane proteins for better immunization and screening
Our Ala-scan epitope mapping service provides mechanism of action data and strengthens IP
We screen antibodies against 6,000 human membrane proteins for deorphaning and de-risking studies
Reporter Virus Particles and other tools to expedite vaccine and antibody development
We offer licensing opportunities for therapeutic antibodies against untapped targets
Trusted by 400+ Companies
Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
